Key Highlights

  • Shares were down 19.47% to USD 10.59 in pre-market trading on November 3, 2026.
  • Third quarter 2026 net sales were USD 142.4 million, up 2.7% from USD 138.7 million.
  • Adjusted EBITDA rose about 7% to USD 28.4 million.
  • 2026 net sales guidance was updated to USD 590 million to USD 595 million.
  • The company made a USD 15.0 million discretionary term Loan prepayment in the quarter.

What Moved the Shares Before the Open (down USD 2.56, 19.47%)

Bioventus (NASDAQ:BVS) was down 19.47% to USD 10.59 in pre-market trading on November 3, 2026, measured against the Monday close. The drop follows the third quarter report issued on November 2, 2026.

Headline profit and Margin figures improved, but Revenue growth was modest. The company has also been reviewing strategic alternatives, so the report may have been read for signals about that process.

The Third Quarter Numbers

According to a company press release dated November 2, 2026, net sales for the quarter ended September 26, 2026 were USD 142.4 million, up 2.7%, or 2.9% in constant currency. Net Income was USD 6.9 million, of which USD 6.0 million was attributable to the company, compared with USD 3.2 million a year earlier.

Adjusted EBITDA was USD 28.4 million against USD 26.6 million. Diluted Earnings per Share were USD 0.08 on a GAAP basis and USD 0.17 on a non-GAAP basis. The company reaffirmed 2026 adjusted earnings per share guidance of USD 0.75 to USD 0.79.

Business Mix and Strategic Review

Bioventus, based in Durham, North Carolina, describes itself as a global leader in innovations for active healing. It reports three segments. Pain Treatments sales were USD 71.3 million, up 6.2%. Surgical Solutions sales were USD 50.5 million, up 0.7%. Restorative Therapies sales were USD 20.6 million, down 3.4% on lower EXOGEN volume.

International sales rose 16.4% to USD 17.8 million, while U.S. sales rose 1.0% to USD 124.6 million. The company said it continues to review potential strategic alternatives, a process that followed an unsolicited Acquisition proposal and other expressions of interest in the second quarter. Strategic alternatives costs were USD 3.6 million in the quarter.

Balance Sheet and Risks

Cash and equivalents were USD 30.7 million on September 26, 2026, down from USD 51.2 million at December 31, 2025. Quarterly cash from operations was USD 20.7 million. Total Debt calculated from the Balance Sheet was about USD 229.8 million, compared with about USD 294.0 million at year-end 2025.

Risks include softer Restorative Therapies sales, a heavily U.S.-weighted revenue base that grew only 1.0%, and the uncertainty of any strategic review, which may or may not lead to a transaction.

What to Watch Next

The company introduced a new 2026 adjusted cash from operations range of USD 84 million to USD 89 million, excluding strategic review costs. Updates on the strategic review, trends in the Pain Treatments segment and further debt reduction are the main items to follow. Pre-market Liquidity is thin, so the opening session may show different price levels.